Our next generation, programed T cell therapies in development

Treating hematological malignancies and solid tumors

The company’s lead therapeutic candidate, obe-cel, is currently being trialed in the potential pivotal FELIX study for adult ALL. Full data for obe-cel in adult ALL is expected in 2022. The opportunity for obe-cel extends beyond adult ALL. Obe-cel is currently being investigated in ongoing clinical studies for B-NHL indications.  Alongside obe-cel, Autolus are progressing a number of pipeline assets both in preclinical and clinical development across hematological malignancies and solid tumors.

Our pipeline


The novel fast off rate CAR in obe-cel drives T cell activity and long-term persistence in the absence of severe immunotoxicity

Find out more

Our products

Autolus are applying our extensive cell programing capability to develop product candidates across hematological malignancies and solid tumors.

Read more